Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans

Circulation

Volumn 114, Issue 15, 2006, Pages 1625-1632

  Gudmundsdóttir, Ingibjörg J ^a   Megson, Ian L ^b   Kell, Jillian S ^a   Ludlam, Christopher A ^a   Fox, Keith A A ^a   Webb, David J ^a   Newby, David E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

Author keywords

Arteries; Blood flow; Platelets; Receptor, PAR 1; Receptor, PAR 2; Veins

Indexed keywords

BRADYKININ; FIBRINOGEN RECEPTOR; NORADRENALIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; SERYLLEUCYLISOLEUCYLGLYCYLLYSYLVALINAMIDE; THROMBIN RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ARTERIAL CIRCULATION; ARTERY DILATATION; ARTERY TONE; ARTICLE; FEMALE; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; VEIN DIAMETER; VEIN DILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY; VEIN TONE; VENOCONSTRICTION; VENOUS CIRCULATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADULT; BLOOD CIRCULATION; CARDIOVASCULAR PHYSIOLOGY; FEMALE; HUMANS; MALE; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PLATELET AGGREGATION; RECEPTOR, PAR-1; RECEPTOR, PAR-2; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR RESISTANCE; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VON WILLEBRAND FACTOR;

EID: 33749642654     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.638478     Document Type: Article

References (32)

1. Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res. 2001;88:989-997.
2. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
3. 2+ mobilization. FEBS Lett. 1991;288:123-128.
4. th helix in signalling: the 7-8-1 receptor activation mechanism. J Biol Chem. 2006;281:4109-4116.
5. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3:1800-1814.
6. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-264.
7. Hollenberg MD, Compton SJ. International Union of Pharmacology, XXVIII: proteinase-activated receptors. Pharmacol Rev. 2002;54:203-217.
8. Chung AWY, Jurasz P, Hollenberg MD, Radomski MW. Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol. 2002;135:1123-1132.
9. Kawabata A, Nakaya Y, Ishiki T, Kubo S, Kuroda R, Sekiguchi F, Kawao N, Nishikawa H, Kawai K. Receptor-activating peptides for PAR-1 and PAR-2 relax rat gastric artery via multiple mechanisms. Life Sci. 2004;75:2689-2702.
10. Griffin C, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science. 2001;293:1666-1670.
11. Cheung WM, Andrade-Gordon P, Derian CK, Damiano BP. Receptor-activating peptides distinguish thrombin receptor (PAR-1) and protease activated receptor 2 (PAR-2) mediated hemodynamic responses in vivo. Can J Physiol Pharmacol. 1998;76:16-25.
12. Damiano BP, Cheung WM, Mitchell JA, Falotico R. Cardiovascular actions of thrombin receptor activation in vivo. J Pharmacol Exp Ther. 1996;279:1365-1378.
13. Kinlough-Rathbone RL, Rand ML, Packham MA. Rabbit and rat platelets do not respond to thrombin receptor peptides that activate human platelets. Blood. 1993;82:103-106.
14. Damiano BP, Derian CK, Maryanoff BE, Zhang HC, Gordon PA. RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev. 2003;21:313-326.
15. Chackalamannil S, Xia Y, Greenlee WJ, Clasby M, Doller D, Tsai H, Asberom T, Czarniecki M, Ahn HS, Boykow G, Foster C, Agans-Fantuzzi J, Bryant M, Lau J, Chintala M. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem. 2005;48:5884-5887.
16. Ebrahimi R, Lincoff AM, Bittl JA, Chew D, Wolski K, Wadhan N, Toggart EJ, Topol EJ. Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis. J Cardiovasc Pharmacol Ther. 2005;10:209-216.
17. Serruys PW, Vranckx P, Allikmets K. Clinical development of bivalirudin (Angiox): rationale for thrombin-specific anticoagulation in percutaneous coronary intervention and acute coronary syndromes. Int J Clin Pract. 2006;60:344-350.
18. Gudmundsdottir IJ, McRobbie SJ, Robinson SD, Newby DE, Megson IL. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation. Biochem Biophys Res Comm. 2005;337:382-385.
19. Crane MS, Rossi AG, Megson IL. A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations. Br J Pharmacol. 2005;144:849-859.
20. Gosselin RC, Dager WE, King JH, Janatpour K, Mahackian K, Larkin EC, Owings JT. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol. 2004;121:593-599.
21. Harding SA, Sarma J, Josephs DH, Cruden NL, Din JN, Twomey PJ, Fox KAA, Newby DE. Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation. 2004;109:1926-1929.
22. Aellig WH. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol. 1981;11:237-243.
23. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost. 1997;78:1242-1248.
24. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KAA, Boon NA, Webb DJ. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation. 1999;99:1411-1415.
25. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation. 2001;104:2177-2181.
26. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation. 1995;92:357-363.
27. Sarma J, Laan CA, Alam S, Jha A, Fox KAA, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation. 2002;105:2166-2171.
28. Tesfamariam B, Allen GT, Normandin D, Antonaccio MJ. Involvement of the "tethered ligand" receptor in thrombin-induced endothelium-mediated relaxations. Am J Physiol Heart Circ Physiol. 1993;265:H1744-H1749.
29. Ku DD, Zaleski JK. Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. J Cardiovasc Pharmacol. 1993;22:609-616.
30. Robin J, Kharbanda R, Mclean P, Campbell R, Vallance P. Protease-activated receptor 2-mediated vasodilatation in humans in vivo: role of nitric oxide and prostanoids. Circulation. 2003;107:954-959.
31. Fujiwara M, Jin E, Ghazizadeh M, Kawanami O. Differential expression of protease-activated receptors 1, 2, and 4 on human endothelial cells from different vascular sites. Pathobiology. 2004;71:52-58.
32. Cleator JH, Zhu WQ, Vaughan DE, Hamm HE. Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP. Blood. 2006;107:2736-2744.